Mikhail Blagosklonny’s hypothesis on dealing with the aging process

Born in 1961, Mikhail Blagosklonny has grown to become a notable person in the field of medicine. He is an Oncologist who spends most of his time studying aging and cancer. He acquired his education from the First Pavlov State Medical University of St. Petersburg, Russia for doctorate and masters in medicine.

He earned his MD in Internal Medicine and his Ph.D. in Cardiology and Experimental Medicine at the same University. He had acquired a good educational background what had remained him to direct what he had learned in the right direction. With this in mind, Mikhail decided to specialize in cardiology and medicine. It became easy for him to begin his career path as he knew what he wanted and was focused.

In 2002, Mr. Blagosklonny was appointed by the New York Medical College as an associate professor. Later, he decided to expound his working experience and joined Ordway Research Institute as a senior scientist.

He gained a lot of experience from working in these two institutions before joining Roswell Park Institute in 2009 as a professor of oncology. His research interest ranges mostly between cancer and cell therapy that can be used to protect other cells from damaging. He has also been seen to study the biology of aging.

Blagosklonny Hypothesis.

When it comes to stopping or reducing the aging process, Mikhail Blagosklonny has formulated a hypothesis on the role Rapamycin. According to his hypothesis, he argues that TOR causes senescence in cells and the process is in a position of converting quiescent cells to become senescent with no damage being incurred on the present molecular cells.

The overstimulation of cell pathways is seen to cause cell resistance that later block the pathways. Mr. Blagosklonny continues to explain how cells hyper-functioning, when coupled with cell resistance, leads to the death of an organism. Thus, he associates hyper function as the primary cause of aging. With that in consideration, he emphasizes the use of Rapamycin drug as it acts as a pro-aging agent and slows down the aging process. He continues to argue that damaging TOR pathways lead this cancer and aging due to molecular damage.

Read more about his profile in LinkedIn.

He believes that in time, he will have a permanent way of reducing the aging process and not a hypothesis. All these he believes will one day be possible as he is committed to finding the solution to this problem.

Leave a Comment

Your email address will not be published. Required fields are marked *